SS-31 Target Population: Cardiovascular Function, Physical Performance, and Mitochondrial Dysfunction
The speaker identifies the populations most likely to benefit from SS-31 as those focused on cardiovascular function, physical performance, and cellular energy production. It is also highlighted as particularly relevant for individuals with conditions directly tied to mitochondrial dysfunction. For a general longevity audience, the speaker specifically calls out cardiac and muscular aging data as compelling justifications for its use.
SS-31 Mechanism Analogy: Restoring Electron Transport Chain Efficiency (Hydroelectric Dam Model)
The speaker uses an analogy to explain SS-31's mechanism: the electron transport chain is compared to turbines in a hydroelectric dam, and cardiolipin represents the structural integrity of the dam itself. As cardiolipin degrades with age, the 'turbines' (ETC complexes) misalign and lose efficiency. SS-31 acts as a repair compound that restores structural alignment and returns energy production to full capacity. No dosage information is provided in this segment.
SS-31 Mechanism: Cardiolipin Binding and Stabilization on the Inner Mitochondrial Membrane
The inner mitochondrial membrane contains a phospholipid called cardiolipin, which plays a critical structural role in the electron transport chain (ETC). With aging, cardiolipin becomes damaged and disorganized, reducing ETC efficiency and dropping energy (ATP) production. SS-31 works by binding directly to cardiolipin, stabilizing it, and restoring the efficiency of the electron transport chain and overall energy production.
SS-31 Target Population: Cardiovascular Function, Physical Performance, and Mitochondrial Dysfunction Conditions
The speaker identifies the populations most likely to benefit from SS-31 as those focused on cardiovascular function, physical performance, and cellular energy production, as well as individuals with conditions directly tied to mitochondrial dysfunction. For the broader longevity audience, cardiac and muscular aging data are cited as particularly compelling justifications for use. No specific clinical trials, dosages, or patient numbers are referenced.
SS-31 and Age-Related Mitochondrial Decline: Cardiolipin Degradation as a Driver of Energy Loss
The speaker identifies age-related cardiolipin damage and disorganization as a key mechanism underlying mitochondrial dysfunction and declining energy production with aging. This positions SS-31 as a potential intervention against a specific molecular hallmark of mitochondrial aging. The claim is presented as established mechanistic understanding rather than citing a specific study, placing it at the expert-opinion tier. No dosage information is provided.
SS-31 Mechanism of Action: Cardiolipin Binding and Electron Transport Chain Stabilization
SS-31 exerts its primary mechanism of action by directly binding to cardiolipin, a phospholipid located on the inner mitochondrial membrane that plays a critical structural role in the electron transport chain (ETC). As mitochondria age, cardiolipin becomes damaged and disorganized, leading to reduced ETC efficiency and declining energy production. SS-31 stabilizes cardiolipin, thereby restoring the structural integrity of the ETC and recovering efficient ATP production. No specific dosage is mentioned in this segment.
SS-31 (Elamipretide) Overview: Synthetic Tetrapeptide Targeting Mitochondrial Function
SS-31, also known as elamipretide (referred to in the transcript as 'lamopretide'), is a synthetic tetrapeptide — meaning it is composed of four amino acids. It is not naturally produced by the human body but was deliberately engineered to target the inner mitochondrial membrane and improve mitochondrial energy production. The speaker presents this as a designed therapeutic compound rather than a naturally occurring or discovered peptide.
Muscular Dystrophy as Accelerated Mitochondrial Dysfunction — Mechanistic Basis for Peptide Use
Dr. Yurth frames muscular dystrophy as an extreme, genetically accelerated form of the same mitochondrial dysfunction that underlies age-related sarcopenia and general muscle-building difficulty. The shared pathology includes excessive reactive oxygen species, impaired satellite cell signaling, inability to regenerate muscle, and chronic low-grade inflammation. This framing justifies using the same peptide protocols — particularly SS-31 — across all these patient populations.
Comprehensive Peptide and Supplement Stack for Muscle Dysfunction and Mitochondrial Failure
Dr. Yurth outlines a comprehensive stacking protocol for patients with muscle-building difficulty, fatigue, muscular dystrophy, or sarcopenia. The core stack includes creatine at 10 grams per day, CoQ10 with geranylgeranyl pyrophosphate (GGPP) for mitochondrial support, SS-31, urolithin A, and exogenous ketones. Peptide adjuncts include growth hormone secretagogues (CJC-1295, ipamorelin, tesamorelin), epitalon, BPC-157, and IGF-1 LR3 for severe cases. She frames this as applicable broadly — not just for muscular dystrophy but for anyone struggling with muscle building or fatigue.
High-Dose or IV SS-31 Recommended for Severe Mitochondrial or Muscle Dysfunction
For severe cases of muscular dystrophy or significant muscle loss, Dr. Yurth suggests that high doses of SS-31 (elamipretide) may be necessary, potentially including intravenous (IV) administration. This represents a dosing escalation recommendation beyond standard subcutaneous use, though specific mg or mcg dosages are not provided.
Peptide Protocol for Muscular Dystrophy Mirrors Protocol for Age-Related Sarcopenia
Dr. Yurth explicitly states that the peptide and supplement protocol for muscular dystrophy is the same as what she uses for sarcopenic elderly patients or anyone struggling to build muscle, because the underlying mechanism — mitochondrial dysfunction — is shared. Muscular dystrophy is framed as an accelerated, genetically-driven version of the same mitochondrial failure seen in aging. This framing broadens the applicability of the SS-31, IGF-1 LR3, BPC-157, and GH secretagogue stack to a wide patient population.
Comprehensive Peptide and Supplement Stack for Muscle Dysfunction and Mitochondrial Disorders
Dr. Yurth outlines a comprehensive stacking protocol for patients with muscular dystrophy, sarcopenia, fatigue, or difficulty building muscle. The core stack includes: creatine at 10 grams per day, CoQ10 with geranylgeranyl pyrophosphate (GGPP) for mitochondrial support, SS-31 (elamipretide), urolithin A, and exogenous ketones. She notes growth hormone secretagogues (CJC, ipamorelin, tesamorelin, ibutamoren) and IGF-1 LR3 as additions for more severe cases, and BPC-157 for angiogenesis and muscle support. This stack is presented as applicable broadly to anyone struggling to build muscle or experiencing fatigue.
SS-31 (Elamipretide) for Mitochondrial Support — Especially Post-COVID
Dr. Yurth uses SS-31, also referred to as a 'lampide' (likely 'lamipeptide' or Elamipretide), to support mitochondrial function, which she states declines with age and has been further impaired in many individuals following COVID-19 infection. She describes SS-31 as cycled rather than used continuously. No dosage or specific cycle length is mentioned in this excerpt.
Stacking Protocol: Thymosin Alpha-1 + Thymosin Beta-4 + BPC-157 + GH Secretagogues + SS-31
Dr. Yurth's personal longevity peptide stack includes Thymosin Alpha-1, Thymosin Beta-4, BPC-157, growth hormone secretagogues, and SS-31, each serving a distinct physiological role (immune, healing, GH axis, and mitochondrial support respectively). BPC-157 is used relatively consistently while the others are cycled, with GH secretagogues specifically avoided in winter. No dosages are provided for any component in this excerpt.
Post-COVID Mitochondrial Dysfunction as Indication for Peptide Therapy
Dr. Yurth makes a clinical observation that COVID-19 infection causes widespread mitochondrial damage, describing it as a 'mitochondrial hit' that affects nearly everyone who was infected. This is presented as a new and broadly applicable indication for mitochondria-targeting peptides such as SS-31. No mechanistic detail or supporting study is cited in this excerpt.
SS-31 (Elamipretide) for Mitochondrial Function — Post-COVID Application
Dr. Yurth uses SS-31 (also referred to as a 'lampide' — likely 'lamipeptide' or Szeto-Schiller peptide) to support mitochondrial function, which she notes declines with age. She specifically highlights the post-COVID context, stating that almost everyone who had COVID suffered a mitochondrial hit, making SS-31 broadly relevant. She cycles SS-31 a couple of times, though the full frequency detail appears cut off in the transcript.
Stacking Protocol: Thymosin Alpha-1 + Thymosin Beta-4 + BPC-157 + SS-31 + GH Secretagogues
Dr. Yurth's personal longevity peptide stack includes Thymosin Alpha-1, Thymosin Beta-4, BPC-157, SS-31, and unspecified growth hormone secretagogues. BPC-157 is used consistently while the others are cycled seasonally. The stack is designed to address immune decline, mitochondrial dysfunction, orthopedic repair, and GH axis support simultaneously.
Post-COVID Mitochondrial Dysfunction as Indication for SS-31
Dr. Yurth identifies post-COVID mitochondrial damage as a widespread concern, suggesting that the majority of people who contracted COVID experienced measurable mitochondrial impairment. She presents SS-31 as a targeted intervention for this specific indication. This is framed as a population-level clinical observation rather than a reference to a specific study.
SS-31 (Elamipretide) for Mitochondrial Function Decline — Including Post-COVID
Dr. Yurth uses SS-31, a mitochondria-targeted peptide also known as elamipretide (referred to as a 'lampide' in the transcript), to address age-related and post-COVID mitochondrial dysfunction. She states that mitochondrial function declines with age and that nearly everyone who had COVID sustained a mitochondrial hit. SS-31 is cycled, used a couple of times per year. No specific dosage is mentioned.
Circannual Rhythm-Based Peptide Cycling Protocol
Dr. Yurth advocates cycling peptides in alignment with circannual (seasonal) biological rhythms, arguing the body has natural phases of growth and hibernation. Winter is described as a hibernation phase where growth-promoting peptides and hormones should not be pushed to high levels. This cycling approach is presented as a core principle of her longevity protocol.
Mitochondrial Peptides (NAD, Mots-c, SS-31) Deemed Unnecessary for Core Goals
The speaker explicitly states he does not use mitochondrial-targeted peptides including NAD, Mots-c, and SS-31, categorizing them as non-essential for his goals. He implies these compounds, while potentially legitimate, are not worth the cost for the average user pursuing body composition and general wellness. No mechanistic or clinical evidence is cited to support or refute their utility.
Cost-Saving Argument Against Complex Multi-Peptide Stacks
The speaker argues that consumers are wasting money by purchasing numerous peptides such as NAD, Mots-c, and SS-31, when a simple two-compound protocol can deliver equivalent or superior results. He claims this simplification can save 'thousands of dollars per month.' This is a cost-efficacy opinion with no comparative clinical or pharmacoeconomic data cited.
Dismissal of Mitochondrial Peptides (NAD, Mots-c, SS-31) as Unnecessary
The speaker explicitly states he does not use NAD, Mots-c ('Matzi'), or SS-31, categorizing them as mitochondrial peptides that are not necessary for his goals. He implies these compounds represent unnecessary spending for most users. This is a dismissal based on personal opinion and self-reported experience, not a controlled comparison.
Evidence-Based Clinical Confidence Ranking: SS-31 > MOTS-c > Humanin
The speaker provides an explicit evidence-based ranking of three mitochondrial peptides by clinical confidence: SS-31 ranks highest (advanced human RCT data), MOTS-c ranks second (first mitochondrial peptide in clinical trials, promising but limited human data), and Humanin ranks third (longest history but mostly preclinical data). The speaker explicitly states this ranking is not a value judgment on effectiveness or importance, nor does it reflect anecdotal reports.
SS-31 Mechanism of Action Is Well Characterized
The speaker notes that SS-31's mechanism of action is well characterized and well documented compared to the other mitochondrial peptides discussed. This mechanistic clarity contributes to its higher clinical confidence ranking. No specific dosage or protocol details are provided in this segment.
Evidence-Based Ranking of Three Mitochondrial Peptides: SS-31 > MOTS-c > Humanin
The speaker provides an explicit evidence-based clinical confidence ranking of three mitochondrial peptides: SS-31 (highest), MOTS-c (promising/intermediate), and Humanin (lowest/most limited human data). The speaker explicitly clarifies this ranking is based solely on the current state of clinical evidence and is not a value judgment on efficacy or importance. Anecdotal reports are also explicitly excluded from this ranking methodology.
SS-31 Mechanism of Action Is Well-Characterized
The speaker notes that SS-31's mechanism of action is not only established but is well-documented in the scientific literature, distinguishing it from the other two peptides discussed. No specific mechanistic details are elaborated upon in this excerpt, but the characterization implies robust peer-reviewed support. This contributes to its top-ranked clinical confidence rating.
Protocol Sourcing Recommendation: 503A Compounding Pharmacy for Peptide Procurement
The speaker recommends obtaining SS-31, MOTS-c, and NAD+ through a 503A compounding pharmacy (as opposed to research chemical websites) as part of a medically supervised protocol. He distinguishes between research site vials (accessible but unsupervised) and pharmacy-compounded peptides prescribed through a medical team, framing the latter as the safer and more effective approach due to proper sequencing guidance. No specific product names, concentrations, or dosages are mentioned.
Mitochondrial Cristae Structural Degradation as Root Cause of Age-Related Energy Decline
The speaker presents mitochondrial cristae (inner membrane folding) degradation as the foundational physical mechanism behind age- and stress-related energy decline, arguing that this structural problem cannot be addressed by conventional supplements. He describes how warped cristae cause inefficient energy conversion and increased ROS production, creating a self-reinforcing cycle of mitochondrial damage. SS-31 is positioned as the only intervention capable of addressing this structural root cause.
Three-Peptide Mitochondrial Protocol: SS-31 → MOTS-c → NAD+ Sequential Stack
The speaker presents a specific three-compound sequential protocol for mitochondrial optimization: Step 1 — SS-31 to repair cristae structure and reduce ROS; Step 2 — MOTS-c to upregulate mitochondrial output and biogenesis; Step 3 — NAD+ to replenish the co-enzyme charge that powers the now-repaired and optimized system. He emphasizes that each layer enables the next and that running them out of order is the primary reason people fail to see results. No dosages, cycle lengths, or specific timing between phases are provided.
SS-31 Reduces Mitochondrial Free Radical (ROS) Production
The speaker claims that by restoring mitochondrial cristae structure, SS-31 reduces the production of reactive oxygen species (free radicals) at the source. The mechanism described is that structurally compromised mitochondria produce unstable molecules that damage surrounding cellular machinery, and SS-31 addresses this by fixing the structural defect rather than scavenging radicals downstream. No dosage is mentioned.
Peptides for Mitochondrial Health Should Be Sourced from Licensed 503A Compounding Pharmacies
The speaker distinguishes between research-site peptide vials (available without prescription) and pharmaceutical-grade peptides obtained through 503A compounding pharmacies under medical supervision. The speaker recommends the latter for patients pursuing this protocol, citing the importance of medical oversight for proper sequencing and quality assurance. This is presented as a safety and efficacy consideration rather than a regulatory warning.
Mitochondrial Structural Degradation as Root Cause of Age-Related Energy Decline
The speaker frames age- and stress-related warping of mitochondrial inner membrane cristae as the foundational physical cause of declining energy that cannot be addressed by lifestyle interventions or conventional supplements. This structural degradation is said to cause both reduced ATP output and increased free radical production, creating a self-reinforcing cycle of mitochondrial damage. SS-31 is positioned as the only intervention that addresses this structural root cause directly.
Three-Compound Mitochondrial Protocol: SS-31 → MOTS-c → NAD+ Sequential Stack
The speaker presents a specific three-compound sequential protocol for mitochondrial optimization: (1) SS-31 first to repair inner mitochondrial membrane structure and reduce oxidative leakage, (2) MOTS-c second to activate mitochondrial biogenesis and increase output once the structural frame is sound, and (3) NAD+ third to replenish the co-enzyme substrate that fuels the now-repaired and optimized mitochondria. The speaker emphasizes that the order is non-negotiable for efficacy and that running them out of sequence is the primary cause of protocol failure. No specific dosages or cycle lengths are provided.
NAD+ Supplementation Is Largely Wasted When Used Before Mitochondrial Structural Repair
The speaker argues that administering NAD+ before repairing mitochondrial membrane integrity results in the co-enzyme being lost through the structural 'leaks' in dysfunctional mitochondria, analogized to charging a battery in a machine that cannot hold charge. This is presented as the primary reason NAD+ is recommended last in the three-compound protocol. The speaker acknowledges NAD+ is often the first compound people try due to its popularity.
SS-31 Reduces Mitochondrial Free Radical Leakage
SS-31 is claimed to reduce the production of reactive oxygen species (free radicals) by restoring mitochondrial membrane structure. The mechanism proposed is that structural disorganization of the inner membrane causes sloppy electron transfer, generating free radicals that damage surrounding cellular machinery. By repairing the structural frame, SS-31 is said to address the root cause of oxidative damage rather than masking it. No dosage information is provided.
SS-31 Repairs Mitochondrial Inner Membrane Structure
SS-31 (Elamipeptide) is described as targeting the inner mitochondrial membrane cristae, stabilizing the structural integrity of the membrane folds where ATP production occurs. By securing the framework of the inner membrane, SS-31 is claimed to allow the electron transport chain machinery to realign properly. This is presented as a prerequisite structural repair before any energy-boosting interventions are applied. No specific dosage or frequency is mentioned.
SS-31 Role: Mitochondrial Repair Agent
SS-31 is introduced as a mitochondria-targeting peptide used in the repair phase prior to MOTS-c administration. Its role is described functionally as restoring mitochondrial integrity before additional cellular stress is applied. No mechanism of action, dosage, or frequency is elaborated upon in this transcript.
Stacking Protocol: SS-31 Before MOTS-c (Repair-Then-Optimize Sequencing)
The speaker recommends a specific sequencing protocol: use SS-31 first to repair mitochondrial function, and only then introduce MOTS-c for optimization. This 'repair before optimization' framework is presented as the correct approach to avoid the adverse outcomes described in anecdotal reports. No dosages, cycle lengths, or transition criteria between the two phases are specified.
Timing Mitochondrial Support Supplements to Recovery Days — Key Protocol Principle
DeLauer's overarching protocol principle is that mitochondrial support supplements — including peptides — should only be taken on recovery days, not training days. On training days, the oxidative stress signal should be left intact to drive adaptation. On recovery days (6–48 hours post-training), mitophagy-supporting compounds can amplify the body's natural cleanup process. This applies to both urolithin A and, by implication, any mitochondrial peptides a user might be taking.
Stacking Warning: Mitochondrial Peptides + Low-Carb/Fasted Training = Oxidative Overload
DeLauer presents a specific stacking risk: combining mitochondrial-stimulating peptides (MoSC, SS31, SLUPP) with low-carb or fasted training creates compounding oxidative stress because fatty acid oxidation already generates more reactive oxygen species than glucose metabolism. He uses the analogy of 'revving an engine already redlining' to describe this danger. The recommendation is to avoid these peptides on hard training days and instead use mitophagy-supporting compounds on recovery days.
Peptides That Spin Up Mitochondria May Cause Oxidative Damage
Thomas DeLauer warns that certain peptides used for mitochondrial support (referencing MoSC, SS31, SLUPP) can over-rev mitochondria, causing oxidative damage rather than recovery. He argues that when combined with low-carb or fasted training — which already increases mitochondrial oxidative stress — these compounds push the system past the hormetic sweet spot into genuine oxidative damage. This is framed as a key risk of stacking aggressive mitochondrial peptides on top of an already stressed system.
Stacking Recommendation: SS-31 Before MOTS-c for Mitochondrial Repair
The speaker recommends using SS-31 (a mitochondria-targeted antioxidant peptide) prior to introducing MOTS-c in individuals with compromised mitochondrial function. The protocol is sequenced: repair mitochondria with SS-31 first, then layer in MOTS-c afterward. No dosages, durations, or cycle lengths are specified for either peptide.
Full Five-Tier Stacking Protocol — Complete Cellular Energy Stack Overview
The speaker outlines a comprehensive five-tier stacking protocol designed for cellular energy optimization. Tier one is foundational supplements; tier two adds NAD+ (50–100 mg SC, 3–5x/week); tier three adds Epitalon (500 mcg–1 mg/day, 10–20 days) and FOXO4-DRI (2–5 mg EOD, 3 doses); tier four adds SS-31 (2 mg/day SC) and MOTS-c (10 mg/week, MWF); tier five conditionally adds Five Amino 1MQ (50–100 mg/day), methylene blue (5–10 mg/day), and injectable L-carnitine (200–500 mg, 3–5x/week). All peptide tiers are cycled eight to twelve weeks on and four to eight weeks off.
Safety Framing — Lifestyle Foundation Is Non-Negotiable Before Peptide Use
The speaker issues a general safety and efficacy caveat that training, nutrition, and sleep must be established before any peptide or supplement protocol is layered on top. The explicit claim is that these protocols enhance existing work but cannot replace it. This functions as a contraindication-adjacent warning against using peptides as a substitute for foundational health behaviors.
Modular Protocol Design — Tiers Can Be Used Independently
The speaker explicitly frames the entire five-tier protocol as modular, meaning individuals do not need to implement all tiers simultaneously to observe results. Each tier is designed to build upon the previous, but partial adoption is presented as valid. This is a structural recommendation rather than a mechanistic or clinical claim.
SS-31 and MOTS-c Concurrent Stack for Core Cellular Energy
The speaker explicitly recommends running SS-31 and MOTS-c concurrently as a combined tier-four energy stack. SS-31 is dosed at 2 mg per day subcutaneous while MOTS-c is dosed at 10 mg per week split three days. Both are cycled identically at eight to twelve weeks on and four to eight weeks off.
SS-31 Subcutaneous Protocol for Mitochondrial Energy Enhancement
SS-31 (also known as Elamipretide) is presented as a core tier-four energy stack peptide targeting mitochondrial function. The recommended dose is approximately 2 mg per day administered subcutaneously. It is cycled on the same schedule as NAD+: eight to twelve weeks on, four to eight weeks off.
Hypothetical Framing of Peptide Dosages as Legal Disclaimer
The speaker repeatedly uses the qualifier 'hypothetically' when stating peptide dosages (SS-31 at 2 mg/day, MOTS-c at 1 mg/day, Cax at 400 mcg/day), framing the recommendations as hypothetical for a 'kangaroo' rather than direct human prescriptions. This appears to be a legal disclaimer strategy. The dosages are nonetheless presented with specificity and clinical intent within the context of a burnout recovery protocol.
NAD+ as Co-Intervention with Peptide Stack for Electron Transport and DNA Repair
NAD+ is described as a critical co-intervention alongside the peptide stack (SS-31 and MOTS-c), serving as the electron acceptor in the glycolytic pathway and electron transport chain. Without NAD+, the speaker states energy production from glucose is impossible. Additionally, NAD+ is identified as a substrate for PARP (poly ADP-ribose polymerase) and sirtuins — repair enzymes that fix oxidative DNA damage caused by burnout. Dosage is 50 mg/day taken together with MOTS-c and SS-31.
Peptide Stack Overloading Warning: Metabolic Chaos from Excessive Compound Stacking
The speaker issues a direct warning against stacking too many compounds simultaneously, including peptides, citing the example of patients taking 14+ supplements including 'a whole bunch of peptides.' He argues this creates metabolic chaos, overloads the liver and kidneys, and adds additional processing burden to already-failing mitochondria. The warning is framed as a safety and efficacy concern: more compounds do not equal more optimization and can actively worsen the underlying mitochondrial failure being treated.
Full Burnout Recovery Stack: SS-31, MOTS-c, NAD+, CoQ10, PQQ, L-Tyrosine, Cax, Magnesium Bisglycinate, L-Theanine
The speaker presents a comprehensive multi-compound protocol targeting each biochemical mechanism of burnout: SS-31 (2 mg/day) and MOTS-c (1 mg/day) for mitochondrial repair; NAD+ (50 mg/day) for electron transport and DNA repair enzyme activation; CoQ10 (200 mg/day) and PQQ (20 mg/day) for electron carrier substrate and biogenesis signaling; L-Tyrosine (3 g/day) as dopamine/norepinephrine precursor; Cax (400 mcg/day morning) for BDNF-mediated dopaminergic recovery; Magnesium Bisglycinate (500 mg before bed) as NMDA antagonist; and L-Theanine (200 mg before bed) for GABA promotion and glutamate excitotoxicity reduction. The speaker states this protocol takes 20–30 days.
SS-31 and MOTS-c Stack for Mitochondrial Furnace Repair
The speaker explicitly recommends stacking SS-31 and MOTS-c together as a combined intervention targeting mitochondrial repair. SS-31 addresses the structural membrane damage while MOTS-c drives biogenesis of new mitochondria. The combined framing is summarized as 'SS31 and MOTS-c repair the furnace.' Dosages are 2 mg/day SS-31 and 1 mg/day MOTS-c, both taken daily.
SS-31 (Elamipretide) for Mitochondrial Membrane Repair in Burnout
SS-31 is described as binding to cardiolipin, the phospholipid layer of the mitochondrial inner membrane that becomes damaged by oxidative stress during burnout. The speaker claims it stabilizes membrane structure, prevents further reactive oxygen species leakage, and reduces new ROS production. A hypothetical dosage of 2 mg every single day is mentioned. The speaker frames this as a targeted intervention for the exact biochemical mechanism of mitochondrial failure.
Foundation-First Safety Principle: Lifestyle Before Peptides
The speaker issues a clear advisory that training, nutrition, and sleep are non-negotiable prerequisites before any peptide or supplement protocol is initiated. Peptides are framed as enhancers of existing healthy behaviors, not replacements for them. This is presented as a foundational safety and efficacy principle throughout the protocol.
Modular Protocol Design: Tiers Can Be Used Independently
The speaker explicitly frames the entire protocol as modular, meaning users do not need to implement all tiers simultaneously to see results. Each tier builds on the previous but can be used in isolation. This is presented as a practical safety and accessibility consideration rather than a clinical recommendation.
SS-31 and MOTS-c Concurrent Stacking for Core Cellular Energy
The speaker explicitly recommends stacking SS-31 and MOTS-c together as the core tier-four energy intervention, running them concurrently rather than sequentially. SS-31 is dosed at ~2 mg/day subcutaneous and MOTS-c at ~10 mg/week (split MWF). Both follow the same eight to twelve weeks on, four to eight weeks off cycling schedule.
SS-31 Subcutaneous Protocol for Mitochondrial Energy Support
SS-31 (Elamipretide) is presented as a core tier-four energy stack peptide targeting mitochondrial function. The recommended dose is approximately 2 mg per day via subcutaneous injection. It is cycled on an eight to twelve weeks on, four to eight weeks off schedule, mirroring the NAD+ cycling protocol.
SS-31 role in mitochondrial repair: structural damage restoration
SS-31 (Elamipretide) is characterized as the 'engine repair' component of the Mechanic Protocol, targeting structural damage in mitochondria. The speaker frames it as complementary to MOTS-c's functional efficiency improvements. No dosage or specific study was cited for SS-31 in this video.
Mechanic Protocol stacking update: SS-31 + MOTS-c concurrent from day one (replaces sequential protocol)
The speaker's original 'Mechanic Protocol' recommended taking SS-31 first to repair mitochondrial structural damage, then adding MOTS-c afterward to optimize. Based on the new animal study showing MOTS-c has direct functional benefits (not just signaling), the speaker now recommends running both peptides simultaneously from day one. The rationale is that SS-31 repairs structural damage while MOTS-c improves functional efficiency — hitting the same problem from two complementary angles. No dosages were mentioned.
SS-31 Dosing Differs for Barth Syndrome vs Therapeutic Use
The standard Barth syndrome dose of ~40 mg/day is not applicable to therapeutic users. Barth syndrome patients lack endogenous mitochondrial repair capacity, requiring much higher doses. Healthy individuals using SS-31 therapeutically need far less (1-5 mg/day).
Cycling Recommendation Is Precautionary, Not Evidence-Based
The speaker states that existing data does not indicate a need to cycle off either SS-31 or MOTS-C. The 8-12 weeks on / 4-8 weeks off cycling recommendation is a precautionary measure due to the absence of long-term human dosing data at these specific doses.
SS-31 Mechanism: Cardiolipin Binding, Not Receptor-Mediated
SS-31 binds to cardiolipin, a lipid molecule in mitochondrial membranes, rather than to a receptor. This means there is no receptor desensitization or downregulation, which theoretically supports continuous use without tolerance development.
SS-31 Therapeutic Dosing Protocol
For therapeutic (non-Barth syndrome) use, SS-31 is recommended at 1-2 mg/day for 4-8 weeks. More aggressive dosing can go up to 5 mg/day. The standard Barth syndrome dose of 40 mg/day is unnecessary for healthy individuals because they retain endogenous mitochondrial repair capacity.
SS-31 + MOTS-C Stacking Recommendation
The speaker recommends stacking SS-31 (daily) with MOTS-C (3x/week) for synergistic mitochondrial benefits. SS-31 at 1-2 mg/day and MOTS-C at 5-15 mg/week split across three doses. For significant age-related decline, doses can be pushed to SS-31 at 5 mg/day and MOTS-C at 15 mg/week. Recommended cycle: 8-12 weeks on, 4-8 weeks off.
Full EBV peptide protocol stack — TA1, KPV, SS-31, MOTS-c with supplements
The complete EBV protocol combines four peptides with nutritional support: Thymosin Alpha-1 (1 mg 2x/week, 12 weeks) for T-cell retraining, KPV (400 mcg 2x/day) for inflammatory cytokine suppression, SS-31 + MOTS-c (stacked) for mitochondrial repair. Supplements include monolaurin (titrate 500 mg to 2-3 g/day), L-lysine (2-3 g/day in 3 doses), selenium (200 mcg/day), and DGL (600 mg/day). A 2022 study (Prusty, Viruses) showed combination antiviral + immune-supportive therapy achieved 67% viral load reduction and 71% symptom improvement sustained at 12-month follow-up.
SS-31 and MOTS-c must be stacked together for mitochondrial recovery
Dr. Bachmeyer explicitly states that SS-31 and MOTS-c need to be used together ('married') for EBV-related mitochondrial dysfunction. SS-31 addresses the structural membrane damage while MOTS-c addresses biogenesis and metabolic software. Without both, recovery from viral-induced mitochondrial damage is incomplete.
SS-31 for protecting mitochondrial membrane from EBV-induced oxidative damage
Chronic EBV infection punches holes in mitochondrial membranes via oxidative stress, causing energy collapse (ATP production reduced 34%, ROS increased 156% per a 2020 Navo study). SS-31 protects the inner mitochondrial membrane from this viral-induced oxidative damage. Dr. Bachmeyer states SS-31 must be paired with MOTS-c for full mitochondrial restoration. No specific dose given for SS-31.